{
  "id": 9306854,
  "title": "Citizens reiterates Remitly stock rating on strong user growth",
  "url": "https://urgent.news/2026/09/23/citizens-reiterates-remitly-stock-rating-on-strong-user-growth",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T09:38:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-remitly-stock-rating-on-strong-user-growth-93CH-4912410"
  },
  "original_language": "en",
  "account": "Citizens upgraded Remitly Global Inc's stock rating to Market Outperform and raised its price target to $32.00 per share. The firm cited Remitly's leading performance compared to competitors, driven by strong user growth and engagement. Active user numbers rose by 20% year-over-year in the first and second quarters, while per-user send volumes increased despite slower website traffic. These trends suggest a growing share of large-dollar senders and a migration of users to the app. The current upside potential stands at about 50% from the stock's current price of $21.28. Remitly has already outperformed, with a 54% increase year-to-date and 31% over the past six months. The company turned profitable in the last year, and InvestingPro indicates the stock remains undervalued. The rating agency offered five additional exclusive tips and a comprehensive research report on the stock. Remitly reported Q2 2026 earnings that beat expectations with $0.93 adjusted earnings per share and $495.2 million in revenue. Analysts reacted positively, with Cantor Fitzgerald raising its price target to $30 and Wolfe Research to $31, citing margin expansion and higher 2027 EBITDA projections.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Citizens reiterates Rapport Therapeutics stock rating on Phase 2 trial potential",
        "url": "https://urgent.news/2026/09/23/citizens-reiterates-rapport-therapeutics-stock-rating-on-phase-2",
        "published": "2026-09-23T09:38:47.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}